News
JMP Securities Initiates Coverage On Prelude Therapeutics with Market Outperform Rating, Announces Price Target of $7
13 Mar 24
News, Price Target, Initiation, Analyst Ratings
12 Health Care Stocks Moving In Friday's Intraday Session
16 Feb 24
Movers
Prelude Therapeutics Reports FY23 Financial Results And Outlines Key Objectives For 2024; FY23 EPS $(2.02) Vs $(2.44) YoY; Current Cash Runway Into 2026 With $232.9M In Cash, Cash Equivalents And Marketable Securities As Of December 31, 2023
15 Feb 24
Earnings, News, Guidance